Monoclate-P^®

Antihemophilic Factor (Human) Factor VIII:C Pasteurized Monoclonal Antibody Purified

• Over a decade of clinical experience and efficacy supported by over 1 billion international units (IU) of use¹
• The manufacturing process combines nature's own design - the human factor VIII molecule - with innovations in laboratory engineering: monoclonal antibody purification and pasteurization designed to remove and inactivate lipid-enveloped and certain non-lipid-enveloped viruses
• A demonstrated level of consistent potency
• Potency ranges, diluent volumes, and peel-off labels designed for patient convenience

Important Safety Information

Monoclate-P^® is contraindicated in patients with known hypersensitivity to mouse protein.

Products of this type are known to cause allergic reactions, mild chills, nausea or stinging at the infusion site. In some cases, inhibitors of FVIII may occur.

Monoclate-P^® is derived from human plasma. As with all plasma-derived products, the risk of transmission of infectious agents, including viruses and, theoretically, the Creutzfeldt-Jakob disease agent, cannot be completely eliminated.

Please see the full prescribing information.

Reference: 1. ZLB Behring. Data on file.

View universal billing codes for Monoclate®

CUSTOMER SUPPORT 1-800-683-1288 or Customer Services

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

Frequently Asked Questions for Monoclate-P^®

• Full Prescribing Information for Monoclate-P^®